Showing 3921-3930 of 10214 results for "".
Meeting the Needs of Today's Injectables Market
https://practicaldermatology.com/series/c-suite-chats/meeting-needs-todays-injectables-market/26926/David Moatazedi, president and CEO of Evolus, talks about trends in the injectables market and the needs of younger generations.Hoya ConBio - Medlite Demo
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/hoya-conbio-medlite-demo/19460/Quick demo on the benefits on using Medlite and how it can improve your practice.Using GEP Test Results to Manage Patients
https://practicaldermatology.com/programs/practical-dermatology-updates-in-skin-cancer/using-gep-test-results-to-manage-patients/35603/Jason M. Rizzo, MD, describes how gene expression profile (GEP) testing works and how the results can be used to manage patients from a dermatologist's perspective.Drs. Rosen and Bhatia Highlight Latest Drugs at Maui Derm
https://practicaldermatology.com/programs/practical-dermatology/drs-rosen-and-bhatia-highlight-latest-drugs-at-maui-derm/32914/The current landscape of therapeutics for dermatologic conditions is dramatic, with new groundbreaking drugs continuously becoming available.Neuromodulators and Dermal Fillers: Dr. Gold
https://practicaldermatology.com/programs/practical-dermatology/neuromodulators-and-dermal-fillers-dr-gold/32694/Michael Gold, MD, talks about the new neurotoxins and applications, as well as fillers, that he covered during "Neuromodulators and Dermal Fillers: What's New, What's Coming and What Are We Doing That's New in 2025" at Maui Derm 2025.Clinical Development of Emrosi for Rosacea
https://practicaldermatology.com/series/c-suite-chats/clinical-development-emrosi-rosacea/32379/Claude Maraoui, President and CEO of Journey Medical, discusses the clinical development program for Emrosi, which was recently approved by the FDA for inflammatory lesions of rosacea in adults.Improving Treatment Capabilities for Vitiligo
https://practicaldermatology.com/series/c-suite-chats/improving-treatment-capabilities-for-vitiligo/29745/David Domzalski, CEO and President of Vyne Therapeutics, discusses what makes vitiligo difficult to treat and how his company is working to address those challenges.Cosmetic Benefits and Post-Treatment
https://practicaldermatology.com/series/pdt-in-practice/cosmetic-benefits-and-post-treatment/29117/Dr. Joel L. Cohen describes the cosmetic benefits of photodynamic therapy and the post-treatment considerations involved.Conversations in Acne, Part 3
https://practicaldermatology.com/topics/acne-rosacea/conversations-in-acne-part-3/19877/What do we know about the anti-inflammatory effects of antibiotics? How can we reduce risks for creating resistance or affecting the gut microbiome? Host Neal Bhatia, MD leads a conversation on these topics and more with Hilary Baldwin, MD and James Q. Del Rosso, DO.Psoriasis Comorbidities
https://practicaldermatology.com/topics/psoriasis/psoriasis-comorbidities/19729/Do you assess the gums of patients with psoriasis? Joel Gelfand, MD explains why periodontal disease may be underappreciated for what it contributes to the psoriatic disease process.